AC Immune SA (NASDAQ:ACIU) Short Interest Up 12.9% in September

AC Immune SA (NASDAQ:ACIU) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 860,900 shares, a growth of 12.9% from the September 15th total of 762,400 shares. Based on an average daily trading volume, of 126,600 shares, the short-interest ratio is currently 6.8 days. Currently, 1.4% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ACIU. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of AC Immune in a report on Wednesday, September 18th. StockNews.com downgraded AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st.

Institutional Investors Weigh In On AC Immune

Several institutional investors have recently modified their holdings of ACIU. Renaissance Technologies LLC lifted its stake in AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after buying an additional 136,300 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in AC Immune by 294.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after buying an additional 328,312 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in AC Immune by 315.6% in the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after buying an additional 8,423 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in AC Immune in the 1st quarter valued at approximately $30,000. Finally, Vanguard Capital Wealth Advisors purchased a new stake in AC Immune in the 2nd quarter valued at approximately $56,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Stock Down 0.3 %

Shares of ACIU stock opened at $3.19 on Thursday. The stock has a market capitalization of $315.49 million, a PE ratio of -4.62 and a beta of 1.25. AC Immune has a 52-week low of $2.20 and a 52-week high of $5.14. The stock’s 50-day moving average price is $3.34 and its 200 day moving average price is $3.40.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $91.60 million. Analysts expect that AC Immune will post -0.89 earnings per share for the current fiscal year.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.